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Abstract
Cholesterol plays a vital role in human body. Its unbalanced homeostasis, however, leads to health related
problems. The elevated blood cholesterol levels are now considered a classic coronary risk factor and
are suspected to lead to coronary artery diseases, causing 2.6 millions of deaths each year. Here, we
develop a two-compartment mathematical model to investigate cholesterol transport in the circulatory
system and its de novo synthesis in the liver. The model is described with a set of two simultaneous
linear diﬀerential equations, which solutions yield changes over time of the cholesterol levels in the liver
(compartment I) and bloodstream (compartment II). We show the applicability of the model to investigate
the processes associated with the high blood cholesterol, e.g. lowering the cholesterol levels by inhibiting
de novo cholesterol synthesis. Taking advantage of the analytically derived relationships for the steady
state (equilibrium), we show how the model could aid diagnosis of high blood cholesterol by identifying
whether the disturbances in the cholesterol homeostasis are due to impaired transport from the liver to the
bloodstream, or vice versa.
Keywords: high blood cholesterol, metabolic syndrome, mathematical modelling
1 Introduction
Cholesterol plays a vital role in human body. It is an essential structural com-
ponent of cell membranes where it modulates membrane permeability and ﬂuidity
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over a range of physiological conditions[1,30]. Furthermore, within cell membranes
it supports the structure of lipid rafts, stabilizing proteins that perform a wealth of
cellular function, including transporting substances into and out of cell, attaching
to and communicating with other cells or responding to endocrine hormones[9,26].
Cholesterol itself is also involved in the modulation of intracellular transport, cell
signalling and nerve conduction[5,19] and acts as an important precursor molecule
in several biochemical pathways[4]. Bile salts are synthesized from the cholesterol
in liver to be stored in gallbladder and released to duodenum to solubilize dietary
lipids, aiding their digestion and absorption[23]. Other cholesterol derivatives in-
clude steroid hormones, both adrenal gland hormones involved i.e. in stress response
and in maintaining body’s salt and water levels and sex hormones such as estrogen,
progesterone or testosterone[10]. In addition, cholesterol is involved in the synthesis
of vitamin D that plays an essential role in the control of calcium and phosphorus
metabolism[4,31].
To provide suﬃcient amount of cholesterol in the human body, ca. 1g of choles-
terol per day is de novo synthesized in human liver and ca. 2-3g is obtained with
food (dietary cholesterol)[24]. Cholesterol is almost insoluble in water and there-
fore by itself cannot freely travel in the bloodstream. To maintain its adequate
and targeted delivery to body sites (cells or tissues), cholesterol is transported in
the circulatory system encapsulated in the lipoprotein complexes that are made of
hydrophobic lipids core surrounded by a shell of more-polar lipids and proteins[6]
(Figure 1). These are classiﬁed according to increasing density as chylomicrons,
chylomicron remnants, very low density lipoproteins (VLDLs), intermediate-density
lipoproteins (ILDs), low-density lipoproteins (LDLs) and high-density lipoproteins
(HDLs)[21]. The body regulates the transport and amount of cholesterol present.
This is done at the various levels and the detailed description is beyond the scope of
this paper, but among others, the increased intake of dietary cholesterol is compen-
sated by the decreased de novo cholesterol synthesis by the feedback regulation of
the amount and activity of 3-hydroxy-3-methylglutaryl CoA reductase (HMG-CoA
reductase), an important intermediate of the cholesterol biosynthesis pathway[4,29].
Unbalanced cholesterol homeostasis leads to health related problems and espe-
cially the elevated blood cholesterol levels are now considered a classic coronary
risk factor and are suspected to lead to the third of the coronary artery disease (top
prevalent disorder) causing 2.6 millions of deaths each year (World Health Orga-
nization). Coronary artery disease is caused by the plaque building up along the
inner walls of the arteries of the heart, narrowing them and reducing blood ﬂow to
the heart[11]. It is believed that it is caused by a chronic inﬂammatory response
in the walls of arteries due to accumulation of macrophages and white blood cells
and promoted by LDLs (bad cholesterol) without the adequate removal of fats and
cholesterol form the macrophages by HDLs (good cholesterol)[16]. At the molec-
ular level the regulation of cholesterol homeostasis is quite complex and not still
fully understood, hence the diagnosis of the underlying problems of the unbalanced
cholesterol transport remain challenging. The elevated blood cholesterol levels are
battled with changes in lifestyles (e.g. reducing the amount of dietary cholesterol,
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increased physical activity) and lowering cholesterol drugs with various modes of
actions (e.g. reducing de novo cholesterol synthesis)[25,27]. However, quite often
ﬁnding the right treatment is based on the trial and error approach. Mathematical
modelling of the cholesterol transport and de novo synthesis could help understand-
ing the underlying mechanisms of the disturbances in the cholesterol homeostasis.
However, this would require modelling of the complex processes, both at the genetic,
molecular (e.g. HMG-CoA reductase eﬀects) and physiological and/or tissue level
(e.g. cholesterol uptake by the liver), whose exact mechanisms are not yet fully
understood[12]. This could reﬂect a very limited number of mathematical models
within the ﬁeld. The previous work included models of lipoprotein dynamics (e.g.
a model of the ﬂuid dynamics of lipid accumulation on the arterial walls[14] and
chemical kinetics of LDL oxidation[7]) as well as of lipoprotein metabolism[2]. Here,
we aim at developing a simple mathematical model of cholesterol transport and de
novo synthesis that could oﬀer insights into high blood cholesterol diagnosis and
treatment.
2 Materials and Methods
2.1 Overview of the current knowledge of cholesterol transport
Based on the literature search, we have identiﬁed and presented the overview of the
current knowledge of cholesterol transport in the lipoproteins (Figure 1). Choles-
terol (C), along triacylglycerols, obtained from diet is carried away from the intestine
in the form of large chylomicrons (CM), the lowest density lipoproteins containing
ca. 90% of triacylglycerols (TAGs) and ca. 4% of cholesterol. In muscles and
other tissues using fatty acids as fuels, triacylglycerols from CM are released as free
fatty acids (FFA) and the liver takes up the cholesterol-rich residues (chylomicron
remnants)[4]. Liver is the major site of de novo cholesterol (and TAGs) synthesis
(in addition to the cholesterol obtained from diet, dietary cholesterol) that is regu-
lated by the cholesterol levels present and the excess of cholesterol is exported into
the blood in the form of VLDLs[12,22]. As in CM, TAGs are hydrolysed by lipases
(released) at the muscles and tissues, transforming VLDLs into IDLs. Half of IDLs
is taken up by the liver and the other half is converted to LDLs by the removal of
more TAGs[4]. LDLs are the major carrier of cholesterol in the blood and their role
is to transport cholesterol to the peripheral tissues and regulate de novo cholesterol
synthesis at these sites. HDLs, on the other hand, binds the esteriﬁed cholesterol
released from the peripheral tissues and transports it back to the liver for the syn-
thesis of bile and steroid hormones[4,21]. Finally, ca. half of the cholesterol in bile
released to digestive tract is recycled, i.e. reabsorbed by the small bowel back into
the bloodstream[4]. The chemical reactions are catalysed by enzymes and regulated
by proteins: ABCA1, cholesterol eﬄux regulatory protein; CEPT, cholesteryl ester
transfer protein; LCAT, lecithin-cholesterol acyltransferase; LIPC, hepatic lipase;
LIPG, endothelial lipase; LPL, lipoprotein lipase; LIPC, hepatic lipase and PLTP,
phospholipid transfer protein.
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Fig. 1. Overview of the keys biochemical processes behind cholesterol transport by lipoproteins. Dietary
and de novo synthesized cholesterol is redistributed to muscles and peripheral tissues (LDLs) as well as
removed from the bloodstream (HDLs) to maintain cholesterol homeostasis.
2.2 Modelling cholesterol circulatory transport and de novo synthesis
To analyse the disturbances in the cholesterol homeostasis we have developed a sim-
ple mathematical model based on the key aspects of the available current knowledge
of cholesterol transport within lipoproteins and its de novo synthesis in the liver
(main site of the de novo cholesterol synthesis). We have simpliﬁed and represented
the biochemical processes shown in Figure 1 in a two-compartment model with the
ﬁrst compartment (I) representing the total cholesterol present in the liver and the
second compartment (II) representing the total cholesterol present in the circulatory
blood (bloodstream) as in Figure 2.
A set of two simultaneous diﬀerential equations describes the rate of changes of
the total amount of cholesterol (m1 and m2) in the two compartments respectively
(Eq.1 and Eq. 2; Figure 2).
dm1
dt
=
k
m1
+ k21m2 − k12m1 +min −mout (1)
dm2
dt
= −k21m2 + k12m1 −mtis +mdiet (2)
The amount of cholesterol in the ﬁrst compartment is dependent on the de novo
cholesterol synthesis (inversely proportional to m1 with rate k), transport of the
cholesterol from compartment II to I (directly proportional to m2 with rate k21,
reverse cholesterol transport), transport of the cholesterol from compartment I to II
(directly proportional to m1 with rate k12),min cholesterol obtained from intestine
O. Hrydziuszko et al. / Electronic Notes in Theoretical Computer Science 306 (2014) 19–3022
Fig. 2. A schematic representation of the two-compartment model of cholesterol transport in the lipopro-
teins; First compartment reﬂects liver, the main site of de novo cholesterol synthesis, the second com-
partment reﬂects bloodstream. Numbers in parentheses indicate corresponding biochemical processes from
Figure 1.
(from membranes of the enterocytes (epithelial cells) that underwent programmed
cell death and recycled from bile acids) and mout cholesterol used as a precursor of
bile acids and being a part (8%) of bile. The amount of cholesterol in the second
compartment is dependent on the transport of the cholesterol between compart-
ments, mtis cholesterol transported to muscles and peripheral tissue (membrane
component) as well as used as a precursors in biochemical reactions (vitamin D,
steroid hormones) and mdiet dietary cholesterol. These two equations embrace in a
simpliﬁed form all the physiological processes in cholesterol transport and de novo
synthesis as outlined in Figure 1 (corresponding processes numbers shown on Figure
2) and their solutions show the changes over time of the total cholesterol in the two
compartments (liver and bloodstream).
2.3 Values of the model parameters
The values of the model parameters were assigned based on the literature search
(for most of the parameters) and mathematically derived (or assumed) given the
known values of the remaining parameters, where literature data were not available
(k12 and k21). The values of model parameters are shown in Figure 3. We have set
the volume of blood in the liver compartment, V1, equal to 12 dl and in the second
compartment, V2, equal to 43 dl (overall 55 dl of blood in the human body)[2]
and assumed no changes in these blood volumes. In addition, we assumed that the
total amount (C2, concentration) of the cholesterol in blood is equal to or below
200 mg/dl, healthy physiological values[11]. The kinetic changes of the parameters
(min, mout, mdiet, mtis) are expressed in mg/min (units of the literature data were
changed (rescaled / recalculated) accordingly given the assumed values of V1 and
V2).
3 Calculations
The set of two simultaneous linear diﬀerential equations has been coded in Matlab
(version 2007b), a high-level technical computing language and environment, and
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Fig. 3. Values of the model parameters: literature derived and calculated.
numerically solved using Runge Kutta Method (ode45 solver). This yielded equa-
tions for the change of total cholesterol (m1 and m2) over time in the corresponding
compartments. We have found the stationary solutions to the diﬀerentiation equa-
tions, i.e. for which there is no change of cholesterol mass over time (dm1/dt = 0
and dm2/dt = 0) (Eq. 3 and Eq. 4).
m∗1 = −
k
mdiet +min −mout −mtis (3)
m∗2 =
m2diet +mdietmin −mdietmout − kk12 − 2mdietmtis −minmtis +moutmtis +m2tis
k21 (mdiet +min −mout −mtis)
(4)
In a special case of no dietary cholesterol (mdiet = 0, e.g. after overnight fasting
or cholesterol free diet), a relationship between the stationary masses (m1
* and m2
*)
can be obtained in the form of Eq. 5.
m∗2 = m
∗
1
kk12 +minmtis −moutmtis −m2tis
kk12
(5)
Using the deﬁnition of concentration as the amount of substance (total choles-
terol mass) per deﬁned space (volume) (C=m/V ), the above equation can be rewrit-
ten for the stationary total cholesterol concentrations in the two compartments
correspondingly (Eq. 6)
C∗2 = C
∗
1
V1
V2
kk12 +minmtis −moutmtis −m2tis
kk12
(6)
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4 Results and Discussion
4.1 Model analysis
The developed two-compartment model allows modelling and analysing a range of
physiological processes related to the high blood cholesterol levels (C2). The high
blood cholesterol levels can be modelled, examined and lowered via changing val-
ues of the model parameter. This can be carried out in the physiological context
since the model parameters represent the underlying biological mechanisms driving
cholesterol transport and de novo synthesis (Figure 1 and Figure 2). Few examples
of model analysis are shown on Figure 4. The expected changes of blood choles-
terol levels (C2) are observed when changing the values of the rates of cholesterol
transport from compartment II to I (from bloodstream to the liver), i.e. increase
and decrease of blood cholesterol levels C2 for k21 = 0.8 min
-1 (lowered, compared
to default k21 = 1 min
-1) and k21= 1.2 min
-1 (increased) respectively (Figure 4a).
In addition, the predicted behaviour of blood cholesterol dynamics can be observed
(Figure 4b). Following a cholesterol-rich meal, blood cholesterol levels (C2) in-
crease 3 h following the meal (during the period of assumed absorption of dietary
cholesterol) and then lower to reach the pre-meal (initial) state. To achieve the
physiological dynamics of the return to the pre-meal state (within 12 h) the values
of mout had to be slightly increased (mout = 1.6 mg/min as oppose to default 1.4
mg/min) to compensate for the fact the model in its current form does not include
the processes associated with the circulation of bile acids. Typically, during a meal,
bile (containing bile acids synthesized from cholesterol in the liver) is discharged
from the gallbladder into the duodenum where it solubilizes fats to aid their ab-
sorption as well as fat-soluble vitamins. Following the meal, cholesterol in the bile
released to the digestive tract is reabsorbed back into the bloodstream (recycled).
To model these processes, a third compartment representing gallbladder would be
needed.
Given the model, it is also possible to investigate the therapeutic strategies to
lower high blood cholesterol. High blood cholesterol levels (C2) obtained due to
high levels of bad cholesterol (by setting the value of mtis to 0 mg/min) can be
counter by inhibiting de novo cholesterol synthesis (by lowering the values of k to
1000 mg/min) (Figure 4c). Statins inhibit HMG-CoA reductase and are the ﬁrst-
line therapy for reducing LDLs blood levels in patients at high risk for coronary
art disease [18]. They have been proven to be able to reduce the 5-year incidence
of major coronary events by about one ﬁfth per mmol/L reduction in blood LDLs
levels[3]. However, they are no side eﬀects free; these tend to be dose related and
include raised liver enzymes and muscle problems[13]. Tailoring the values of the
model parameters to an individual patient could help selecting the optimal dosage
of statins and predict the expected cholesterol levels during the treatment. Another
way to counter the increased blood cholesterol levels is to reduce the activity of
CETP, plasma lipid transfer protein that facilitates the transport of cholesterol and
TGAs between the diﬀerent fractions of lipoproteins. This can be modelled by
simultaneously adjusting the values of rates of cholesterol transport between the
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Fig. 4. Examples of the modelling possibilities showing changes in the blood cholesterol levels: a) increase
and decrease of the blood cholesterol due to changes in the rates of cholesterol transport from bloodstream
to the liver alone; solid line: decreased rates (k21 = 0.8 min-1), dashed line: increased rates (k21 = 1.2
min-1); b) increase of blood cholesterol levels following uptake of dietary cholesterol (absorption up to 3 h
following a meal); solid line: mdiet = 1 mg/min, dashed line: mdiet = 1mg/min and increased mout= 1.6
mg/min; c) eﬀect of the increased cholesterol level due to decreased cholesterol transport to muscles and
peripheral tissues and decreased usage as a precursor of vitamin D and steroid hormones (mtis = 0 mg/min,
solid line) and counter-acting this increase by decreasing de novo cholesterol synthesis (k = 1000 mg2/min,
dashed line) and d) increase of blood cholesterol levels due to lowering the activity of the CETP protein
(k12 = 3.3 min-1 and k21=1.3 min-1)
two compartments (lowering k12 to 3.3 mg/min and increasing k21 to 1.3 mg/min)
(Figure 4d). Here, the model could be used to test novel drugs regulating the
activity of CETP. No such drugs are used in the current medical practise, yet few
are being tested in the clinical trials (dalcetrapib, anacetrapib)[15]. It is believed
that reducing activity of CETP can not only lower the blood levels of LDLs, but
also increase the levels of HDLs (good cholesterol) and restoring the physiological
balance between the lipoproteins fractions[28]. However, the relationship between
lipoproteins metabolism, pharmacologic CETP inhibition and the development of
coronary artery diseases requires further elucidation.
4.2 Diagnostic signiﬁcance
An advantage of modelling the cholesterol transport and de novo synthesis in a form
of a simple two-compartment model is that it can be easily described by the two
simultaneous linear diﬀerential equations, for which the exact analytic solutions in
the steady state (equilibrium) can be obtained (Eq.3 and Eq.4). Furthermore, these
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analytic solutions can be used to ﬁnd relationships between the model parameters
(e.g. Eq. 6). The sensitivity analysis to these equilibrium solutions showed that
the model is not very sensitive to changes of the values of the cholesterol mass
parameters of min, mout and mtis and the rate of de novo cholesterol synthesis
k. The changes of these values (0 < min < 1 mg/min, 0 < mout < 1 mg/min, 0
< mtis < 0.4 mg/min, and 0 < k < 2000 mg
2/min) yield only a small response
of the cholesterol concentration ratio (C2
*/C1
*) - in the order of magnitude of 4
(10-4)(data not shown). However, a model has proved to be sensitive to the changes
of the values of the rates of cholesterol transport between the two compartments
(k12 and k21) (Figure 5). Changing the values of k12 and k21 from 0 to double their
normal, equilibrium state values (0 < k21 < 2 and 0 < k12 < 5) gave exponential-like
(or power) and linear responses for k21 and k12 respectively.
The rates of cholesterol exchange (transport) between the two compartments are
the key parameters aﬀecting the cholesterol concentration and hence are of potential
diagnostic application. Screening for high blood cholesterol levels is recommended
for all patients with coronary artery diseases or their risk factors (e.g. men aged
45 years or older, women aged 55 years or older, family history of coronary artery
diseases, hypertension or smoking) and lipoprotein panel blood tests provides results
on the measures of lipids, including total cholesterol and its fractions (incl. HDLs
and LDLs)[20]. The elevated cholesterol, in particularly the LDL fraction can be
lowered by up to 15% by changes in lifestyle (diet and exercise) and by up to 50%
and up to 60% with the maximum dosages of statins and cholesterol-absorption
inhibitors respectively[25]. However, not all patients respond well or at all to the
medications, and selection of doses as well as a type of treatment is quite often
conduced via a trial and error approach. In these problematic patients, according to
our model, the measurement of the cholesterol concentration ratio (C2
*/C1
*) could
be informative of the underlying causes of the high blood cholesterol. In particular,
low values (C2
*/C1
*<< 1) indicate problems with transport of cholesterol from liver
to the bloodstream, that is with processes such as releasing the excess cholesterol
from the liver in the form of VLDLs or hydrolysing by lipases TAGs at the muscles
and tissues and transforming VLDLs into IDLs (processes labelled on Figure 1 as
6 and 7). High values (C2
*/C1
* >> 1), on the other indicate the problems with
transport of cholesterol from bloodstream to the liver including processes such as
i) the maturation process of HDLs molecules (from pre 1 HDL via pre 2 HDL and
HDL3 into HDL2, with apolipoprotein (Apo) A1 peptides (principal component of
HDLs) acting as recognition sites by the LCAT and PLTP enzymes in this process),
ii) uptake of mature HDL2s by the liver, iii) induction of cholesterol eﬄux from
macrophages inside artery walls by ABCA1 gene or iv) uptake by IDLs by the
liver (processes labelled on Figure 1 as 8-14 and 16-17)[8]. The knowledge of the
direction of the underlying cause of high blood cholesterol (either disturbance of
cholesterol transport from the liver to bloodstream or vice versa) could be essential
in the further diagnostics and treatment of some of the patients in which ﬁnding
lowering cholesterol interventions are not straightforward. In these patients, the
measurement of the cholesterol levels in the blood from the hepatic portal vein or
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Fig. 5. Plot of equilibrium solutions vs. the changes in the rates of cholesterol transport: a) from compart-
ment II to I and b) from compartment I to II. Low levels of the cholesterol ratio (C2*/C1* << 1) indicate
that the underlying cause of the disturbances of the cholesterol homeostasis are due to impaired transport
of cholesterol from compartment I to II; high levels (C2*/C1* >> 1) point towards the impaired transport
from compartment II to I.
based on the liver biopsy, a more invasive way than the standard blood test, could
provide the essential insights into the underlying causes of disturbance of cholesterol
homeostasis and direct further diagnosis (e.g. genetic testing of mutations in HDLs
and LDLs receptors or the main apolipoproteins components (ApoA1 in HDLs, or
ApoB in chylomicrons and LDLs).
5 Conclusions
Maintaining cholesterol homeostasis is a complex process that takes place at the
genetic, cellular and tissue levels. Disturbances in the cholesterol balance, espe-
cially high levels of blood cholesterol levels lead to coronary artery diseases and are
estimated to cause 2.6 millions of deaths each year. Furthermore, statins, lower-
ing de novo cholesterol synthesis, are the most common prescribed medications, all
showing that our cholesterol health is of importance. Whereas many mathematical
models have been developed to better understand the mechanism of glucose-insulin
regulatory system [17] (of similar complexity and signiﬁcance as cholesterol, leading
to another prevalent disease, namely diabetes), the modelling approaches to choles-
terol homeostasis are limited. Here, we showed that even modelling the keys aspects
behind cholesterol homeostasis in the two-compartment model enables investigation
of the elevated blood cholesterol levels in the physiological and diagnostic context.
We have showed that the changes in the blood cholesterol levels can be obtained
in the predictive fashion, when changing the values of the model parameters. Fur-
thermore, we demonstrated the models potential to investigate diﬀerent treatment
strategies to lower high blood cholesterol values (via reduction of de novocholesterol
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synthesis or reduction of the activity of the CETP protein). Finally, taking advan-
tage of being able to ﬁnd analytic solutions to the stationary states, we derived
the potential relationship between the ratio of cholesterol levels in the blood and
liver (C2
*/C1
*) that could be signiﬁcance when pinpointing the underlying causes
of cholesterol homeostasis.
Presenting a relatively simple two-compartment model of cholesterol transport
and de novo synthesis, we would like to highlight the importance of mathematical
modelling in improving understanding of the cholesterol homeostasis as well as in
aiding the diagnosis and treatment of the life-treating high blood cholesterol levels.
Advanced models could not only help to elucidate the relationships between reg-
ulation of cholesterol homeostasis at the gene, cellular and tissue level, but could
bring us a step closer to a personalized medicine in preventing and treating high
cholesterol levels. We have now started developing such advanced model by focusing
ﬁrst on the inclusion of the aforementioned function of the gallbladder.
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